Home
Pipeline&Products
Science&Innovation
Recombinant IgG Cleaving Enzyme
Recombinant Human Hyaluronidase
Solutions
Investor Relations
Listing documents
Announcement and Circular Letter
Performance Report
Corporate Governance
Investor Contact
Media
About Us
Our Stories
Join Us
Contact Us
简
繁
EN
Home
Pipeline&Products
Science&Innovation
Recombinant IgG Cleaving Enzyme
Recombinant Human Hyaluronidase
Solutions
Media
About Us
Our Stories
Join Us
Contact Us
Investor Relations
Listing documents
Announcement and Circular Letter
Performance Report
Corporate Governance
Investor Contact
简
繁
EN
请输入您要查找的信息
热门关键词：
透明质酸酶
皮下给药
Announcement and Circular Letter
Responding to urgent patient needs
Innovating for diverse health challenges
Listing documents
Announcement and Circular Letter
Performance Report
Announcement and Circular Letter
2026.04.27
2025 ANNUAL REPORT
2026.04.08
VOLUNTARY ANNOUNCEMENT - HUMAN HYALURONIDASE FOR INJECTION APPROVED FOR MARKETING BY THE NMPA
2026.04.02
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
2026.03.25
VOLUNTARY ANNOUNCEMENT - COMPLETION OF PHASE III CLINICAL TRIAL FOLLOW-UP OF KJ103 FOR DESENSITIZATION IN KIDNEY TRANSPLANTATION
2026.03.16
DATE OF BOARD MEETING
2026.03.12
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPROVAL FOR NEW INDICATION OF KJ101
2026.03.09
VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE STOCK LIST UNDER THE STOCK CONNECT
2026.03.04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
«
1
2
3
»
